GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Tax Provision

Incyte (LTS:0J9P) Tax Provision : $-241 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Incyte Tax Provision?

Incyte's tax provision for the three months ended in Sep. 2024 was $-50 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $-241 Mil.

Incyte Tax Provision Historical Data

The historical data trend for Incyte's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Tax Provision Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.89 -63.48 378.14 -188.46 -236.62

Incyte Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.53 -69.88 -66.61 -54.82 -50.07

Incyte Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-241 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Tax Provision
Comparable Companies
SRPT INSM RPRX BMRN PCVX TECH UTHR SMMT ROIV VKTX VRTX REGN ASX:CSL XKRX:207940 XBRU:UCB ALNY XBRU:ARGX XKRX:068270 BNTX BGNE
Traded in Other Exchanges
INCY:USA INCY:Mexico 1INCY:Italy ICY:Germany ICY:Germany I1NC34:Brazil
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Website
https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines